This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone quarter ended September 30, 2026: revenue up 30.4%, PAT up 14.9%
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone revenue for the quarter ended September 30, 2026 rose 30.4% to Rs 7,291.0 million from Rs 5,590.9 million a year earlier; PAT rose 14.9% to Rs 623.3 million from Rs 542.2 million. Standalone half-year revenue rose 30.1% to Rs 14,118.9 million, while PAT fell 9.0% to Rs 1,001.6 million. Exceptional charges were Rs 149.6 million. The Rs 1,486.6 million NPPA demand is disputed; no provision was made and the court paused collection.
Quarterly revenue growth helps, but half-year PAT fell 9.0%, exceptional charges were Rs 149.6 million, and the disputed NPPA demand may cap gains.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹729.1 Cr | ₹559.1 Cr | +30.4% |
| Operating profit | ₹88.33 Cr | ₹71.94 Cr | +22.8% |
| Profit after tax | ₹62.33 Cr | ₹54.22 Cr | +15.0% |
| EBITDA margin | 11.1% | 12.5% | −1.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.